Clinical Trials and Cohort Studies Grants
Funding Providers
National Health and Medical Research Council (NHMRC)
Location
Australia WideFunding Type
Cash grant G17780
Primary Category
ResearchEligible to
- Not-for-Profits
- Universities
- Businesses
- State/Territory Governments
Funding
Total pool: $70,000,000 (approx)Round(s)
Currently Closed
- Opens 10-Sep-2025 Closes 05-Nov-2025
Purpose
Clinical Trials and Cohort Studies Grants support high-quality clinical trials and cohort studies that address important gaps in knowledge, leading to relevant and implementable findings for the benefit of human health.
Overview
This funding scheme is open to research proposals for clinical trials and/or cohort studies of any size – that is, they may be large or small clinical trials or cohort studies.
The intended outcomes of the Clinical Trials and Cohort Studies Grants scheme are improvements in health and well-being, health care practice or policy, as a result of:
- High-quality clinical trials that provide reliable evidence of the effects of health-related interventions on health outcomes (or appropriate surrogates).
- High-quality cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes.
- High quality retrospective cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes.
Funding
The provisional funding allocation for Clinical Trials and Cohort Studies Grants 2023 is $70 million. NHMRC’s Research Committee annually reviews and recommends indicative budget amounts to be awarded across individual funding schemes.
Limitations
Eligibility
Applications will only be accepted from NHMRC approved Administering Institutions. A list of NHMRC approved Administering Institutions is available at: https://www.nhmrc.gov.au/funding/manage-your-funding/nhmrcs-administering-institutions.
Who is eligible to apply for a grant?
Chief Investigators and Associate Investigators
The maximum number of CIs allowed on a Clinical Trials and Cohort Studies Grants 2023 application is ten.
- Chief Investigator ‘A’
At the time of acceptance and for the duration of a grant the CIA must be an Australian or New Zealand citizen, or a permanent resident of Australia, or have an appropriate work visa in place. The CIA must also be based in Australia for at least 80% of the funding period.
- Chief Investigators
The role and contribution of each CI must be described in the grant application. PhD students may be named as CIs where the PhD student is critical for the successful completion of the proposed research. CIs are expected to remain on the grant activity for the duration of the grant, unless a variation is approved by NHMRC in accordance with the NHMRC Grantee Variations Policy. NHMRC will only approve a change in CIs in exceptional circumstances and a variation request must not be used as a means to meet NHMRC eligibility requirements.
- Associate Investigators
An Associate Investigator (AI) is defined as an investigator who provides some intellectual and/or practical input into the research and whose participation may warrant inclusion of their name on any outputs (e.g. publications). There is no restriction on who may be named as an AI on an application. However, a maximum number of 10 can be entered in Sapphire.
Applications / Guidelines
Contact Details
- Phone: 1800 500 983
- Email: help@nhmrc.gov.au
We take pride in ensuring our data is up to date and accurate, but you should not rely on our data alone. Please double-check important information on the funder's website before applying.